fasudil has been researched along with Osteosarcoma in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, Y | 1 |
| Cai, X | 1 |
| Fan, J | 1 |
| Zhang, L | 1 |
| Li, Z | 1 |
| Ren, J | 1 |
| Wu, G | 1 |
| Zhu, F | 1 |
1 other study available for fasudil and Osteosarcoma
| Article | Year |
|---|---|
RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2017 |